Angiotech Pharmaceuticals Files $250 Million Mixed Shelf
July 24, 2009 (FinancialWire) — Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) has filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement with the U.S. Securities and Exchange Commission to allow Angiotech to offer up to $250 million during the next 25 months.
The offerings may consist of common shares, class I preference shares, debt securities, warrants or units and will be made to potential purchasers in British Columbia, Ontario and the United States.
Angiotech plans to use the proceeds from any such offering for general corporate purposes, including funding research and development programs, capital expenditures, working capital and/or repayment or refinancing of the company’s outstanding indebtedness.
Vancouver-based Angiotech Pharmaceuticals is a specialty pharmaceutical and medical device company with over 1,500 dedicated employees.
Angiotech discovers, develops and markets treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
